



Helsinki, 17 September 2019

Addressee:

Decision number: CCH-D-2114484966-27-01/F

Substance name: 3-({[(4-methylphenyl)sulfonyl]carbamoyl}amino)phenyl 4-

methylbenzenesulfonate EC number: 432-520-2 CAS number: 232938-43-1

Registration number: Submission number:

Submission date: 20/11/2018
Registered tonnage band:

#### **DECISION ON A COMPLIANCE CHECK**

Based on Article 41 of Regulation (EC) No 1907/2006 (the REACH Regulation), ECHA requests you to submit information on:

- 1. Pre-natal developmental toxicity study (Annex IX, Section 8.7.2.; test method: OECD TG 414) in a first species (rat or rabbit), oral route with the registered substance;
- 2. Simulation testing on ultimate degradation in surface water (Annex IX, Section 9.2.1.2.; test method: Aerobic mineralisation in surface water simulation biodegradation test, EU C.25./OECD TG 309) at a temperature of 12 °C with the registered substance
- 3. Identification of degradation products (Annex IX, 9.2.3.) using an appropriate test method with the registered substance;

You have to submit the requested information in an updated registration dossier by **24 March 2021**. You shall also update the chemical safety report, where relevant.

The reasons of this decision are set out in Appendix 1. The procedural history is described in Appendix 2 and advice and further observations are provided in Appendix 3.



#### **Appeal**

This decision can be appealed to the Board of Appeal of ECHA within three months of its notification. An appeal, together with the grounds thereof, has to be submitted to ECHA in writing. An appeal has suspensive effect and is subject to a fee. Further details are described under: <a href="http://echa.europa.eu/regulations/appeals">http://echa.europa.eu/regulations/appeals</a>.

Authorised<sup>1</sup> by Claudio Carlon, Head of Unit, Hazard Assessment

<sup>&</sup>lt;sup>1</sup> As this is an electronic document, it is not physically signed. This communication has been approved according to ECHA's internal decision-approval process.



#### **Appendix 1: Reasons**

# 1. Pre-natal developmental toxicity study (Annex IX, Section 8.7.2.) in a first species

In accordance with Articles 10(a) and 12(1) of the REACH Regulation, a technical dossier registered at per year must contain, as a minimum, the information specified in Annexes VII to IX to the REACH Regulation. The information to be generated for the dossier must fulfil the criteria in Article 13(4) of the same regulation.

A "pre-natal developmental toxicity study" (test method OECD TG 414) for a first species is a standard information requirement as laid down in Annex IX, Section 8.7.2. of the REACH Regulation. Adequate information on this endpoint needs to be present in the technical dossier for the registered substance to meet this information requirement.

You have sought to adapt this information requirement with the following justification for the adaptation:

"A OECD 421 reprotoxicity screening study was performed. The study did not indicate any relevant adverse effects to the offspring nor reduced litter size, mortality of newborns etc. The only effects seen were slightly reduced body weight of the pups in the highest dose group. This effect occurred at a dose that induced toxic effects to the dams. It is concluded from these isolated findings in pups that the likelihood of teratogenic effects or relevant disturbances of offspring development is not likely. With respect to these conclusions and animal welfare considerations it is suggested to waive the developmental toxicity study."

ECHA notes that your adaptation does not meet any of the specific rules for adaptation of Annex IX, Section 8.7.2., column 2 nor the general rules for adaptation of Annex XI. In the waver justification you refer to the findings of a "reproduction/ developmental toxicity screening test" (test method: OECD TG 421) that you have provided in the technical dossier for the "Toxicity to reproduction" endpoint. However, this study does not provide the information required by Annex IX, Section 8.7.2., because it does not cover key parameters of a pre-natal developmental toxicity study, such as examinations of foetuses for skeletal and visceral alterations.

Therefore, your adaptation of the information requirement is rejected.

As explained above, the information provided on this endpoint for the registered substance in the technical dossier does not meet the information requirement. Consequently there is an information gap and it is necessary to provide information for this endpoint.

According to the test method OECD TG 414, the rat is the preferred rodent species and the rabbit the preferred non-rodent species. On the basis of this default assumption ECHA considers testing should be performed with rats or rabbits as a first species.

ECHA considers that the oral route is the most appropriate route of administration for substances except gases to focus on the detection of hazardous properties on reproduction as indicated in ECHA *Guidance on information requirements and chemical safety assessment* (version 6.0, July 2017) Chapter R.7a, Section R.7.6.2.3.2. Since the substance to be tested is a solid, ECHA concludes that testing should be performed by the oral route.

# **CONFIDENTIAL** 4 (9)



Therefore, pursuant to Article 41(1) and (3) of the REACH Regulation, you are requested to submit the following information derived with the registered substance subject to the present decision: Pre-natal developmental toxicity study (test method: OECD TG 414) in a first species (rat or rabbit) by the oral route.

# 2. Simulation testing on ultimate degradation in surface water (Annex IX, Section 9.2.1.2.)

In accordance with Articles 10(a) and 12(1) of the REACH Regulation, a technical dossier registered at per year must contain, as a minimum, the information specified in Annexes VII to IX to the REACH Regulation. The information to be generated for the dossier must fulfil the criteria in Article 13(4) of the same regulation.

"Simulation testing on ultimate degradation in water" is a standard information requirement as laid down in Annex IX, section 9.2.1.2. of the REACH Regulation. Adequate information on this endpoint needs to be present in the technical dossier for the registered substance to meet this information requirement.

You have sought to adapt this information requirement according to Annex IX, Section 9.2, column 2. You provided the following justification for the adaptation: 'The test substance was found to be non-biodegradable in an OECD 301F study ( 1999). This result is supported by another biodegradation study. Hence, it can be expected that the test substance is not biodegradable in simulation tests either. Therefore, simulation tests in water and sediments are not provided.'

However, ECHA notes that your adaptation does not meet the specific rules for adaptation of Column 2 of Annex IX, Section 9.2. According to Annex IX, Section 9.2.1.2, column 2 of the REACH Regulation, simulation testing on ultimate degradation in surface water does not need to be conducted if the substance is highly insoluble in water or is readily biodegradable. ECHA notes that based on the information in the technical dossier, the registered substance is not readily biodegradable in the OECD 301B key study (<10% after 28 days) and it has a water solubility of 34.7mg/l and so is not highly insoluble in water.

In general, t simulation tests on degradation in water provide information on the rate of degradation of a substance under environmentally relevant conditions.. The ready biodegradation tests monitor only ultimate biodegradation (i.e. by carbon dioxide evolution in the OECD 301B key study and by oxygen consumption in the OECD 301F and OECD 301C supporting studies) and do not give information on primary degradation or other environmental transformation processes. Furthermore, there is evidence from the inherent biodegradation supporting study (OECD 302B) that the registered substance is lost from the test media: i.e. DOC removal of 73% is reported after 3 hours and >99% after 28 days, which you attribute to adsportion of the test material. ECHA considers that it cannot be concluded that the substance would not be degraded in a simulation test on ultimate degradation in water.

Furthermore, ECHA considers that the information is needed for the PBT/vPvB assessment and for the identification of the degradation products in relation to the PBT/vPvB assessment.

### **CONFIDENTIAL** 5 (9)



As explained above, the information provided on this endpoint for the registered substance in the technical dossier does not meet the information requirements. Consequently there is an information gap and it is necessary to provide information for this endpoint.

According to ECHA Guidance on information requirements and chemical safety assessment, Chapter R.7b (version 4.0, June 2017) Aerobic mineralisation in surface water – simulation biodegradation (test method EU C.25. / OECD TG 309) is the preferred test to cover the standard information requirement of Annex IX, Section 9.2.1.2.

One of the purposes of the simulation test is to provide the information that must be considered for assessing the P/vP properties of the registered substance in accordance with Annex XIII of the REACH Regulation to decide whether it is persistent in the environment. Annex XIII also indicates that "the information used for the purposes of assessment of the PBT/vPvB properties shall be based on data obtained under relevant conditions". The Guidance on information requirements and chemical safety assessment R.7b (version 4.0, June 2017) specifies that simulation tests "attempt to simulate degradation in a specific environment by use of indigenous biomass, media, relevant solids [...], and a typical temperature that represents the particular environment". The Guidance on information requirements and chemical safety assessment Chapter R.16 on Environmental Exposure Estimation, Table R.16-8 (version 3.0 February 2016) indicates 12°C (285K) as the average environmental temperature for the EU to be used in the chemical safety assessment. Performing the test at the temperature of 12°C is within the applicable test conditions of the Test Guideline OECD TG 309. Therefore, the test should be performed at the temperature of 12°C.

In the OECD TG 309 Guideline two test options, the "pelagic test" and the "suspended sediment test", are described. ECHA considers that the pelagic test option should be followed as that is the recommended option for P assessment. The amount of suspended solids in the pelagic test should be representative of the level of suspended solids in EU surface water. The concentration of suspended solids in the surface water sample used should therefore be approximately 15 mg dw/L. Testing natural surface water containing between 10 and 20 mg SPM dw/L is considered acceptable. Quantification of non-extractable residues (NER) is also recommended in surface water simulation degradation studies. Furthermore, when reporting NER in your test results you should explain and scientifically justify the extraction procedure and solvent used obtaining a quantitative measure of NER as described in Guidance on information requirements and chemical safety assessment R.7b (version 4.0, June 2017) and R.11 (version 3.0, June 2017.

Therefore, pursuant to Article 41(1) and (3) of the REACH Regulation, you are requested to submit the following information derived with the registered substance subject to the present decision: Aerobic mineralisation in surface water – simulation biodegradation test (test method: EU C.25./OECD TG 309).

### Notes for your consideration

Before conducting the requested test you are advised to consult the ECHA Guidance on information requirements and chemical safety assessment, Chapter R7b, Sections R.7.9.4 and R.7.9.6 (version 4.0, June 2017) and Chapter R.11, Section R.11.4.1.1 (version 3.0, June 2017) on PBT assessment.

#### **CONFIDENTIAL** 6 (9)



In accordance with Annex I, Section 4, of the REACH Regulation you should revise the PBT assessment when results of the test detailed above are available. You are also advised to consult the ECHA Guidance on information requirements and chemical safety assessment (version 3.0, June 2017), Chapter R.11, Section R.11.4.1.1. and Figure R. 11-3 on PBT assessment for the integrated testing strategy for persistency assessment in particular taking into account the degradation products of the registered substance.

# 3. Identification of degradation products (Annex IX, 9.2.3.)

In accordance with Articles 10(a) and 12(1) of the REACH Regulation, a technical dossier registered at per year must contain, as a minimum, the information specified in Annexes VII to IX to the REACH Regulation. The information to be generated for the dossier must fulfil the criteria in Article 13(4) of the same regulation.

The identification of the degradation products is a standard information requirement according to column 1, Section 9.2.3. of Annex IX of the REACH Regulation. Adequate information on this endpoint needs to be present in the technical dossier for the registered substance to meet this information requirement.

The biodegradation section in the technical dossier does not contain any information in relation to the identification of degradation products, nor an adaptation in accordance with column 2 of Annex IX, Sections 9.2 or 9.2.3. or with the general rules of Annex XI for this standard information requirement.

According to Annex IX, Section 9.2.3., column 2 of the REACH Regulation, identification of degradation products is not needed if the substance is readily biodegradable. ECHA notes that based on the information in the technical dossier, the registered substance is not readily biodegradable as also discussed in section 2 above.

Furthermore, ECHA notes that you have not provided any justification in your chemical safety assessment (CSA) or in the technical dossier for why there is no need to provide information on the degradation products. ECHA considers that this information is needed in relation to the PBT/vPvB assessment and risk assessment.

As explained above, the information provided on this endpoint for the registered substance in the technical dossier does not meet the information requirements. Consequently there is an information gap and it is necessary to provide information for this endpoint.

Regarding appropriate and suitable test method, the methods will have to be substance-specific. When analytically possible, identification, stability, behaviour, molar quantity of metabolites relative to the parent compound should be evaluated. In addition, degradation half-life, log Kow and potential toxicity of the metabolite may be investigated. You may obtain this information from the relevant degradation studies also requested in this decision, or by some other measure. You will need to provide a scientifically valid justification for the chosen method.

Therefore, pursuant to Article 41(1) and (3) of the REACH Regulation, you are requested to submit the following information derived with the registered substance subject to the present decision:

# **CONFIDENTIAL** 7 (9)



Identification of the degradation products (Annex IX, Section 9.2.3.) by using an appropriate and suitable test method, as explained above in this section.

Notes for your consideration

Before providing the above information you are advised to consult the ECHA Guidance on information requirements and chemical safety assessment (version 4.0, June 2017), Chapter R.7b., Sections R.7.9.2.3 and R.7.9.4. These guidance documents explain that the data on degradation products is only required if information on the degradation products following primary degradation is required in order to complete the chemical safety assessment. Section R.7.9.4. further states that when substance is not fully degraded or mineralised, degradation products may be determined by chemical analysis.

# **CONFIDENTIAL** 8 (9)



#### **Appendix 2: Procedural history**

For the purpose of the decision-making, this decision does not take into account any updates of your registration after the date when the draft decision was notified to you under Article 50(1) of the REACH Regulation.

The compliance check was initiated on 26 September 2018.

The decision making followed the procedure of Articles 50 and 51 of the REACH Regulation, as described below:

ECHA notified you of the draft decision and invited you to provide comments within 30 days of the notification.

ECHA did not receive any comments within the 30 days.

ECHA notified the draft decision to the competent authorities of the Member States for proposals for amendment.

As no amendments were proposed, ECHA took the decision according to Article 51(3) of the REACH Regulation.



#### Appendix 3: Further information, observations and technical guidance

- 1. The substance subject to the present decision is provisionally listed in the Community rolling action plan (CoRAP) for the start of substance evaluation in 2020.
- 2. This compliance check decision does not prevent ECHA from initiating further compliance checks on the present registration at a later stage.
- 3. Failure to comply with the requests in this decision will result in a notification to the enforcement authorities of your Member State.
- 4. In carrying out the tests required by the present decision, it is important to ensure that the particular sample of substance tested is appropriate to assess the properties of the registered substance, taking into account any variation in the composition of the technical grade of the substance as actually manufactured or imported. If the registration of the substance covers different grades, the sample used for the new tests must be suitable to assess these.

Furthermore, there must be adequate information on substance identity for the sample tested and the grades registered to enable the relevance of the tests to be assessed.

